The US giant will pay the money upfront for distribution rights for SSGJ-707 outside of China; the deal could be worth up to $4.8bn and Pfizer will also invest $100m into the HKEX listed firm.

The dual listing will help keep momentum in Hong Kong's equity markets, with the majority of the $4.5bn proceeds raised by the Shenzhen based global EV player set to help build a factory in Hungary; a greenshoe option takes the raising to $5.2bn.

Shilpa Gulrajani, DBS' head of sustainable finance, institutional banking, offered her thoughts on how capital markets are aligning with the region’s transition needs, including green loans and blended finance, on the sidelines of Ecosperity Week.

The issuance from the Hong Kong conglomerate, formerly known as NWS Holdings, was to finance the redemption of its outstanding offshore capital securities by its subsidiary.

Standard Chartered is providing full FX services with more services expected in Q4; FA understands that FalconX will partner with more banks soon.

Exports grew 15% in Q1, however there is expected to be a slowdown moving forward as tariffs bite, the baht remains strong and tourism faces headwinds.

Minority owner Partners Group said the IPO proceeds will be used to further grow the Hangzhou-headquartered restaurant's 493 outlets and establish a centralised food processing facility; Clifford Chance, Citi and CMB International Capital were involved in the deal.

Clean energy investments are ramping up in Apac, but a $800bn annual shortfall risks slowing momentum. At Temasek’s Ecosperity Week, IFC's Riccardo Puliti and BlackRock's Susan Chan called for bolder partnerships, clearer policies, and better capital mobilisation.

$400m has been allocated to support Digital Halo, which has assets in the Philippines and Malaysia; the Swiss PE firm is also expanding its data centre footprint in Australia.

Markets have rallied after a weekend agreement to reduce tariffs to 10% in China and 30% in the US is good news for companies, markets, and the US dollar; however, pharmaceutical stocks are in focus as US president Donald Trump tries to reduce drug prices.